Venlafaxine and its interaction with WAY 100635: Effects on serotonergic unit activity and behavior in cats

European Journal of Pharmacology

Volumn 404, Issue 1-2, 2000, Pages 121-132

  Bjorvatn, Bjørn ^a,b   Fornal, Casimir A ^a   Martı́n, Francisco J ^a   Metzler, Christine W ^a   Jacobs, Barry L ^a  

^a PRINCETON UNIVERSITY   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

(Cat); 5 HT syndrome; 5 HT(1A) autoreceptor; 5 HT(5 hydroxytryptamine, serotonin); Dorsal raphe nucleus; Venlafaxine; WAY 100635

Indexed keywords

AUTORECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN; SEROTONIN 1A RECEPTOR; VENLAFAXINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AROUSAL; ARTICLE; CAT; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; ELECTROPHYSIOLOGY; MALE; NEGATIVE FEEDBACK; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SINGLE UNIT ACTIVITY;

AMINOPYRIDINES; ANIMALS; BEHAVIOR, ANIMAL; CATS; CYCLOHEXANOLS; DRUG INTERACTIONS; MALE; NEURONS; PIPERAZINES; PYRIDINES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SODIUM CHLORIDE;

EID: 0034666602     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00622-1     Document Type: Article

References (51)

1. Andrews J.M., Ninan P.T., Nemeroff C.B. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression. 4:1996;48-56.
2. Artigas F. Selective serotonin/noradrenaline reuptake inhibitors (SNRIs): pharmacology and therapeutic potential in the treatment of depressive disorders. CNS Drugs. 4:1995;79-89.
3. 1A antagonists. Trends Neurosci. 19:1996;378-383.
4. Auerbach S.B., Lundberg J.F., Hjorth S. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacology. 34:1995;89-96.
5. Baraban J.M., Aghajanian G.K. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology. 19:1980;355-363.
6. Béïque J.-C., de Montigny C., Blier P., Debonnel G. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse. 32:1999;198-211.
7. Bel N., Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J. Pharmacol. Exp. Ther. 278:1996;1064-1072.
8. 1A autoreceptors and increases dorsal raphe unit activity in awake cats. Eur. J. Pharmacol. 356:1998;167-178.
9. Blier P., Bergeron R. The use of pindolol to potentiate antidepressant medication. J. Clin. Psychopharmacol. 59(Suppl. 5):1998;16-23.
10. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
11. Blier P., de Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7:1987;24S-35S.
12. Bogdanski D.F., Weissbach H., Udenfriend S. Pharmacological studies with the serotonin precursor, 5-hydroxytryptophan. J. Pharmacol. Exp. Ther. 122:1958;182-194.
13. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
14. Briley M., Moret C. Antidepressant properties of specific serotonin-noradrenaline reuptake inhibitors. Skolnick P. Antidepressants: New Pharmacological Strategies. 1997;35-52 Humana Press, Totowa, NJ.
15. Daws L.C., Toney G.M., Gerhardt G.A., Frazer A. In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters. J. Pharmacol. Exp. Ther. 286:1998;967-976.
16. 1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur. J. Pharmacol. 345:1998;41-46.
17. 1A receptor antagonism. Neuropharmacology. 38:1999;1153-1163.
18. Delgado P.L., Moreno F.A. Role of norepinephrine in depression. J. Clin. Psychiatry. 61(Suppl. 1):2000;5-12.
19. Fornal C.A., Jacobs B.L. Physiological and behavioral correlates of serotonergic single-unit activity. Osborne N.N., Hamon M. Neuronal Serotonin. 1988;305-345 Wiley, New York, NY.
20. 1A agonist and antagonist drug administration in behaving cats. J. Pharmacol. Exp. Ther. 270:1994;1345-1358.
21. Fornal C.A., Metzler C.W., Gallegos R.A., Veasey S.C., McCreary A.C., Jacobs B.L. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY 100135. J. Pharmacol. Exp. Ther. 278:1996;752-762.
22. Fornal C.A., Martin F.J., Metzler C.W., Jacobs B.L. Pindolol, a putative 5-hydroxytryptamine1A antagonist, does not reverse the inhibition of serotonergic neuronal activity induced by fluoxetine in awake cats: comparison to WAY-100635. J. Pharmacol. Exp. Ther. 291:1999;220-228.
23. Fornal C.A., Martin F.J., Metzler C.W., Jacobs B.L. Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats. J. Pharmacol. Exp. Ther. 291:1999;229-238.
24. 1A receptor antagonist, WAY-100635. Eur. J. Pharmacol. 281:1995;81-88.
25. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115:1995;1064-1070.
26. 1A autoreceptors and noradrenergic mechanisms. Psychopharmacology. 130:1997;261-268.
27. Gur E., Dremencov E., Lerer B., Newman M.E. Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur. J. Pharmacol. 372:1999;17-24.
28. Haskins J.T., Moyer J.A., Muth E.A., Sigg E.B. DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity. Eur. J. Pharmacol. 115:1985;139-146.
29. Invernizzi R., Belli S., Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res. 584:1992;322-324.
30. Jacobs B.L. An animal behavior model for studying central serotonergic synapses. Life Sci. 19:1976;777-785.
31. Lewis D.I., Coote J.H. Evidence that the firing pattern of sympathetic preganglionic neurones is determined by an interaction between amines and an excitatory amino acid. Boll. - Soc. Ital. Biol. Sper. 72:1996;279-294.
32. Mann J.J. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology. 21:1999;99S-105S.
33. Martin L.P., Jackson D.M., Wallsten C., Waszczak B.L. Electrophysiological comparison of 5-hydroxytryptamine1A receptor antagonists on dorsal raphe cell firing. J. Pharmacol. Exp. Ther. 288:1999;820-826.
34. McCall R.B., Aghajanian G.K. Serotonergic facilitation of facial motoneuron excitation. Brain Res. 169:1979;11-27.
35. Meltzer H. Serotonergic dysfunction in depression. Br. J. Psychiatry. 155:1989;25-31.
36. Mills K.C. Serotonin syndrome. Am. Fam. Physician. 25:1995;1474-1482.
37. Mongeau R., Blier P., de Montigny C. The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res. Rev. 23:1997;145-195.
38. Morton W.A., Sonne S.C., Verga M.A. Venlafaxine: a structurally unique and novel antidepressant. Ann. Pharmacother. 29:1995;387-395.
39. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E.M., Nielsen S.T., Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35:1986;4493-4497.
40. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283:1997;1305-1322.
41. 1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenylaminopropane)-2 (DOI). Neurosci. Lett. 115:1990;74-80.
42. Preskorn S.H., Janicak P.G., Davis J.M., Ayd F.J. Jr. Advances in the pharmacotherapy of depressive disorders. Janicak P.G., Davis J.M., Preskorn S.H., Ayd F.J. Jr. Principles and Practice of Psychopharmacotherapy. 1995;1-24 Williams & Wilkins, Baltimore, MD.
43. Rodriguez R., Rojas-Ramirez J.A., Drucker-Colin R.R. Serotonin-like actions of quipazine on the central nervous system. Eur. J. Pharmacol. 24:1973;164-171.
44. 1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci. Lett. 219:1996;123-126.
45. Smith J.E., Lakoski J.M. Electrophysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus. Eur. J. Pharmacol. 323:1997;69-73.
46. Smith L.M., Peroutka S.J. Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome. Pharmacol. Biochem. Behav. 24:1986;1513-1519.
47. Sporer K.A. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 13:1995;94-104.
48. Tricklebank M.D., Forler C., Fozard J.R. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur. J. Pharmacol. 106:1985;271-282.
49. Wallach M.B., Friedman E., Gershon S. 2,5-Dimethoxy-4-methylamphetamine (DOM), a neuropharmacological examination. J. Pharmacol. Exp. Ther. 182:1972;145-154.
50. White S.R., Neuman R.S. Facilitation of spinal motoneurone excitability by 5-hydroxytryptamine and noradrenaline. Brain Res. 188:1980;119-127.
51. Yamada J., Sugimoto Y., Horisaka K. The behavioral effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur. J. Pharmacol. 154:1988;299-304.